FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2340691868> ?p ?o ?g. }

• W2340691868 endingPage "411" @default.
• W2340691868 startingPage "401" @default.
• W2340691868 abstract "Monoamine oxidase B (MAO-B) inhibitors and dopamine receptor agonists are common first-line treatment options in early Parkinson's disease (PD).To evaluate the efficacy and safety of rotigotine transdermal patch as an add-on therapy to an MAO-B inhibitor in patients with early-PD.In two Phase III, randomized, double-blind, placebo-controlled studies in early-PD (SP512, SP513), patients were randomized to rotigotine (titrated to optimal dose ≤8 mg/24 h) or placebo, and maintained for 24 (SP512) or 33 (SP513) weeks. Post hoc analyses were performed on pooled data for patients receiving an MAO-B inhibitor (selegiline) at a stable dose at randomization and throughout the studies, with groups defined as Selegiline+Rotigotine and Selegiline+Placebo. Outcome measures included change from baseline in Unified Parkinson's Disease Rating Scale (UPDRS) II (activities of daily living), III (motor), UPDRS II+III and responders (patients achieving ≥20%, ≥25% or ≥30% decrease in UPDRS II+III). As post hoc analyses, p-values are exploratory.130 patients were evaluable for efficacy analyses (Selegiline+Rotigotine: 84, Selegiline+Placebo: 46). Combined treatment with rotigotine and selegiline improved UPDRS III and UPDRS II+III scores versus selegiline alone (LS-mean [95% CI] treatment difference for UPDRS III: -4.89 [-7.87 to -1.91], p = 0.0015; for UPDRS II+III: -5.76 [-9.71 to -1.82], p = 0.0045). Higher proportion of patients in the Selegiline+Rotigotine group were classified as ≥20%, ≥25% or ≥30% responders (all p < 0.001). Combined treatment appeared more effective in patients aged ≤65 years versus > 65 years (although patient numbers in the subgroups were low). Adverse event profile was consistent with the known safety profile of rotigotine.In these post hoc analyses, adjunctive treatment with rotigotine in patients already receiving an MAO-B inhibitor improved UPDRS II+III score; this appeared to be largely driven by improvements in the motor aspects of PD." @default.
• W2340691868 created "2016-06-24" @default.
• W2340691868 creator A5004004308 @default.
• W2340691868 creator A5021705851 @default.
• W2340691868 creator A5027360698 @default.
• W2340691868 creator A5039274182 @default.
• W2340691868 creator A5091050492 @default.
• W2340691868 date "2016-05-26" @default.
• W2340691868 modified "2023-09-26" @default.
• W2340691868 title "Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson’s Disease: A Post Hoc Analysis" @default.
• W2340691868 cites W1834321437 @default.
• W2340691868 cites W1974309226 @default.
• W2340691868 cites W1981410074 @default.
• W2340691868 cites W1997274212 @default.
• W2340691868 cites W2000450717 @default.
• W2340691868 cites W2001142484 @default.
• W2340691868 cites W2006957728 @default.
• W2340691868 cites W2029879331 @default.
• W2340691868 cites W2031450416 @default.
• W2340691868 cites W2033522112 @default.
• W2340691868 cites W2036584054 @default.
• W2340691868 cites W2051860167 @default.
• W2340691868 cites W2053085095 @default.
• W2340691868 cites W2054155867 @default.
• W2340691868 cites W205634292 @default.
• W2340691868 cites W2061879368 @default.
• W2340691868 cites W2074028222 @default.
• W2340691868 cites W2095583386 @default.
• W2340691868 cites W2098749010 @default.
• W2340691868 cites W2102262133 @default.
• W2340691868 cites W2106350754 @default.
• W2340691868 cites W2108901766 @default.
• W2340691868 cites W2117471184 @default.
• W2340691868 cites W2128364757 @default.
• W2340691868 cites W2132307715 @default.
• W2340691868 cites W2135340312 @default.
• W2340691868 cites W2157257950 @default.
• W2340691868 cites W2169741346 @default.
• W2340691868 cites W2189551121 @default.
• W2340691868 cites W2606572887 @default.
• W2340691868 cites W51088050 @default.
• W2340691868 doi "https://doi.org/10.3233/jpd-150758" @default.
• W2340691868 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4927859" @default.
• W2340691868 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27061066" @default.
• W2340691868 hasPublicationYear "2016" @default.
• W2340691868 type Work @default.
• W2340691868 sameAs 2340691868 @default.
• W2340691868 citedByCount "6" @default.
• W2340691868 countsByYear W23406918682017 @default.
• W2340691868 countsByYear W23406918682018 @default.
• W2340691868 countsByYear W23406918682020 @default.
• W2340691868 countsByYear W23406918682023 @default.
• W2340691868 crossrefType "journal-article" @default.
• W2340691868 hasAuthorship W2340691868A5004004308 @default.
• W2340691868 hasAuthorship W2340691868A5021705851 @default.
• W2340691868 hasAuthorship W2340691868A5027360698 @default.
• W2340691868 hasAuthorship W2340691868A5039274182 @default.
• W2340691868 hasAuthorship W2340691868A5091050492 @default.
• W2340691868 hasBestOaLocation W23406918681 @default.
• W2340691868 hasConcept C126322002 @default.
• W2340691868 hasConcept C142724271 @default.
• W2340691868 hasConcept C168563851 @default.
• W2340691868 hasConcept C204243189 @default.
• W2340691868 hasConcept C204787440 @default.
• W2340691868 hasConcept C205679159 @default.
• W2340691868 hasConcept C27081682 @default.
• W2340691868 hasConcept C2775842315 @default.
• W2340691868 hasConcept C2776134090 @default.
• W2340691868 hasConcept C2779134260 @default.
• W2340691868 hasConcept C2779424955 @default.
• W2340691868 hasConcept C2779734285 @default.
• W2340691868 hasConcept C42219234 @default.
• W2340691868 hasConcept C67761136 @default.
• W2340691868 hasConcept C71924100 @default.
• W2340691868 hasConcept C98274493 @default.
• W2340691868 hasConceptScore W2340691868C126322002 @default.
• W2340691868 hasConceptScore W2340691868C142724271 @default.
• W2340691868 hasConceptScore W2340691868C168563851 @default.
• W2340691868 hasConceptScore W2340691868C204243189 @default.
• W2340691868 hasConceptScore W2340691868C204787440 @default.
• W2340691868 hasConceptScore W2340691868C205679159 @default.
• W2340691868 hasConceptScore W2340691868C27081682 @default.
• W2340691868 hasConceptScore W2340691868C2775842315 @default.
• W2340691868 hasConceptScore W2340691868C2776134090 @default.
• W2340691868 hasConceptScore W2340691868C2779134260 @default.
• W2340691868 hasConceptScore W2340691868C2779424955 @default.
• W2340691868 hasConceptScore W2340691868C2779734285 @default.
• W2340691868 hasConceptScore W2340691868C42219234 @default.
• W2340691868 hasConceptScore W2340691868C67761136 @default.
• W2340691868 hasConceptScore W2340691868C71924100 @default.
• W2340691868 hasConceptScore W2340691868C98274493 @default.
• W2340691868 hasIssue "2" @default.
• W2340691868 hasLocation W23406918681 @default.
• W2340691868 hasLocation W23406918682 @default.
• W2340691868 hasLocation W23406918683 @default.
• W2340691868 hasLocation W23406918684 @default.
• W2340691868 hasOpenAccess W2340691868 @default.
• W2340691868 hasPrimaryLocation W23406918681 @default.

• next